JP6967528B2 - 抗補体Ｂｂ因子抗体及びその使用 - Google Patents

抗補体Ｂｂ因子抗体及びその使用 Download PDF

Info

Publication number
JP6967528B2
JP6967528B2 JP2018552076A JP2018552076A JP6967528B2 JP 6967528 B2 JP6967528 B2 JP 6967528B2 JP 2018552076 A JP2018552076 A JP 2018552076A JP 2018552076 A JP2018552076 A JP 2018552076A JP 6967528 B2 JP6967528 B2 JP 6967528B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018552076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513726A (ja
JP2019513726A5 (enExample
Inventor
サンディップ パニカー，
グラハム パリー，
カレン スー クリストファーソン，
トニー サンヨン ビュン，
Original Assignee
バイオベラティブ ユーエスエー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオベラティブ ユーエスエー インコーポレイテッド filed Critical バイオベラティブ ユーエスエー インコーポレイテッド
Publication of JP2019513726A publication Critical patent/JP2019513726A/ja
Publication of JP2019513726A5 publication Critical patent/JP2019513726A5/ja
Priority to JP2021147485A priority Critical patent/JP7326393B2/ja
Application granted granted Critical
Publication of JP6967528B2 publication Critical patent/JP6967528B2/ja
Priority to JP2023126155A priority patent/JP2023139289A/ja
Priority to JP2025194917A priority patent/JP2026069789A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018552076A 2016-04-04 2017-04-03 抗補体Ｂｂ因子抗体及びその使用 Active JP6967528B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021147485A JP7326393B2 (ja) 2016-04-04 2021-09-10 抗補体Ｂｂ因子抗体及びその使用
JP2023126155A JP2023139289A (ja) 2016-04-04 2023-08-02 抗補体Ｂｂ因子抗体及びその使用
JP2025194917A JP2026069789A (ja) 2016-04-04 2025-11-14 抗補体Ｂｂ因子抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317897P 2016-04-04 2016-04-04
US62/317,897 2016-04-04
PCT/US2017/025784 WO2017176651A1 (en) 2016-04-04 2017-04-03 Anti-complement factor bb antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021147485A Division JP7326393B2 (ja) 2016-04-04 2021-09-10 抗補体Ｂｂ因子抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2019513726A JP2019513726A (ja) 2019-05-30
JP2019513726A5 JP2019513726A5 (enExample) 2020-05-07
JP6967528B2 true JP6967528B2 (ja) 2021-11-17

Family

ID=60000646

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018552076A Active JP6967528B2 (ja) 2016-04-04 2017-04-03 抗補体Ｂｂ因子抗体及びその使用
JP2021147485A Active JP7326393B2 (ja) 2016-04-04 2021-09-10 抗補体Ｂｂ因子抗体及びその使用
JP2023126155A Pending JP2023139289A (ja) 2016-04-04 2023-08-02 抗補体Ｂｂ因子抗体及びその使用
JP2025194917A Pending JP2026069789A (ja) 2016-04-04 2025-11-14 抗補体Ｂｂ因子抗体及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021147485A Active JP7326393B2 (ja) 2016-04-04 2021-09-10 抗補体Ｂｂ因子抗体及びその使用
JP2023126155A Pending JP2023139289A (ja) 2016-04-04 2023-08-02 抗補体Ｂｂ因子抗体及びその使用
JP2025194917A Pending JP2026069789A (ja) 2016-04-04 2025-11-14 抗補体Ｂｂ因子抗体及びその使用

Country Status (23)

Country Link
US (3) US10934347B2 (enExample)
EP (1) EP3452510A4 (enExample)
JP (4) JP6967528B2 (enExample)
KR (2) KR102673420B1 (enExample)
CN (2) CN116790614A (enExample)
AU (2) AU2017246794B2 (enExample)
BR (1) BR112018070357A2 (enExample)
CA (1) CA3019332A1 (enExample)
CL (1) CL2018002810A1 (enExample)
CO (1) CO2018010827A2 (enExample)
CR (1) CR20180529A (enExample)
DO (1) DOP2018000219A (enExample)
EA (1) EA201892225A1 (enExample)
EC (1) ECSP18082302A (enExample)
IL (3) IL262010B (enExample)
MA (1) MA44878A (enExample)
MX (2) MX2018012176A (enExample)
MY (1) MY194603A (enExample)
PE (1) PE20190209A1 (enExample)
PH (1) PH12018502137A1 (enExample)
SG (1) SG11201808525UA (enExample)
TN (1) TN2018000341A1 (enExample)
WO (1) WO2017176651A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012016073A2 (en) 2010-07-28 2012-02-02 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
IL309260B2 (en) 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
AU2017246794B2 (en) 2016-04-04 2024-07-04 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
BR112019009495A2 (pt) * 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
BR112019009484A2 (pt) 2016-12-09 2019-07-30 Gliknik Inc otimização de fabricação de gl-2045, um stradomer multimerizador
JP2020518240A (ja) * 2017-01-17 2020-06-25 ザ テキサス エー アンド エム ユニバーシティー システム 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
CN111527105B (zh) * 2017-10-11 2024-10-25 美国比奥维拉迪维股份有限公司 诱导补体活性的方法
JP7403165B2 (ja) * 2017-12-19 2023-12-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血液脳関門を通過してウイルスベクターを送達するための方法および組成物
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
KR20220042128A (ko) * 2019-06-27 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-cd53 조성물 및 방법, 그리고 이의 용도
JP7631296B2 (ja) * 2019-07-17 2025-02-18 ジェミニ・セラピューティクス・サブ・インコーポレイテッド Ｈ因子増強性抗体及びその使用
US20230050339A1 (en) * 2020-02-18 2023-02-16 Children's Hospital Medical Center Compositions and methods for treating liver disease
TWI900560B (zh) 2020-04-20 2025-10-11 美商健臻公司 人類化抗補體因子bb抗體及其用途
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
SG119177A1 (en) 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
WO1996019487A1 (en) 1994-12-22 1996-06-27 Nissan Chemical Industries, Ltd. Organobismuth derivatives and process for producing the same
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DE69708318T3 (de) 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6046305A (en) 1997-12-12 2000-04-04 Macromed, Inc. Heterofunctionalized star-shaped poly(ethylene gycols) for protein modification
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP2340850A1 (en) 2004-02-10 2011-07-06 The Regents of the University of Colorado, a Body Corporate Inhibition of factor B, the alternative complement pathway and methods related thereto
EP1771205B1 (en) 2004-06-18 2016-10-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
SI1964852T1 (sl) * 2005-12-20 2013-09-30 Sbi Biotech Co. Ltd. Proti-ilt7 protitelo
WO2007071061A1 (en) * 2005-12-23 2007-06-28 Viventia Biotech Inc. Methods for generating and screening fusion protein libraries and uses thereof
US8981060B2 (en) * 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
AU2008323939A1 (en) * 2007-11-08 2009-05-14 Genentech, Inc. Anti-factor B antibodies and their uses
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US20110288011A1 (en) 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
EP2755688A4 (en) 2011-10-27 2014-08-06 Nkt Therapeutics Inc HUMANIZED ANTIBODIES AGAINST INKT
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
US9243070B2 (en) * 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
WO2014044793A2 (en) * 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
ES2912396T3 (es) * 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
AU2015223056B2 (en) * 2014-02-27 2020-10-01 Allergan, Inc. Complement Factor Bb antibodies
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
AU2017246794B2 (en) 2016-04-04 2024-07-04 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
CN111527105B (zh) 2017-10-11 2024-10-25 美国比奥维拉迪维股份有限公司 诱导补体活性的方法
TWI900560B (zh) 2020-04-20 2025-10-11 美商健臻公司 人類化抗補體因子bb抗體及其用途

Also Published As

Publication number Publication date
TN2018000341A1 (en) 2020-06-15
MX2023007149A (es) 2023-06-28
US11851482B2 (en) 2023-12-26
JP7326393B2 (ja) 2023-08-15
JP2019513726A (ja) 2019-05-30
DOP2018000219A (es) 2019-03-31
IL295288A (en) 2022-10-01
ECSP18082302A (es) 2019-01-31
JP2021191789A (ja) 2021-12-16
EP3452510A1 (en) 2019-03-13
AU2017246794B2 (en) 2024-07-04
JP2026069789A (ja) 2026-04-24
KR20190003951A (ko) 2019-01-10
US10934347B2 (en) 2021-03-02
SG11201808525UA (en) 2018-10-30
CO2018010827A2 (es) 2018-11-22
AU2024224000A1 (en) 2024-12-19
BR112018070357A2 (pt) 2019-01-29
MA44878A (fr) 2019-03-13
US20240228599A1 (en) 2024-07-11
JP2023139289A (ja) 2023-10-03
CN109563158A (zh) 2019-04-02
IL295288B2 (en) 2024-08-01
NZ747018A (en) 2025-05-02
CR20180529A (es) 2019-03-21
CL2018002810A1 (es) 2019-03-15
KR20240096672A (ko) 2024-06-26
IL262010A (en) 2018-10-31
CA3019332A1 (en) 2017-10-12
MX2018012176A (es) 2019-02-07
PE20190209A1 (es) 2019-02-07
US20210221877A1 (en) 2021-07-22
US20190153079A1 (en) 2019-05-23
MY194603A (en) 2022-12-06
WO2017176651A1 (en) 2017-10-12
KR102673420B1 (ko) 2024-06-07
IL262010B (en) 2022-09-01
PH12018502137A1 (en) 2019-09-23
CN116790614A (zh) 2023-09-22
AU2017246794A1 (en) 2018-10-25
IL295288B1 (en) 2024-04-01
CN109563158B (zh) 2022-08-09
EP3452510A4 (en) 2020-01-15
EA201892225A1 (ru) 2019-09-30
IL311675A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
JP7326393B2 (ja) 抗補体Ｂｂ因子抗体及びその使用
AU2019200448B2 (en) Anti-complement C1s antibodies and uses thereof
JP2022537672A (ja) 抗ｂ７－ｈ３抗体およびその使用方法
CA3189730A1 (en) Anti-tigit antibody and methods of use thereof
HK40063408A (en) Anti-complement c1s antibodies and uses thereof
HK40006720A (en) Anti-complement factor bb antibodies and uses thereof
NZ786930A (en) Anti-complement factor Bb antibodies and uses thereof
BR122026004905A2 (pt) Anticorpos recombinantes específicos contra o fator bb do complemento e uso dos mesmos, composição farmacêutica e recipiente

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200327

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211025

R150 Certificate of patent or registration of utility model

Ref document number: 6967528

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250